Free Trial

Mainz Biomed (MYNZ) Competitors

Mainz Biomed logo
$1.48 -0.06 (-3.90%)
Closing price 04:00 PM Eastern
Extended Trading
$1.49 +0.01 (+0.68%)
As of 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MYNZ vs. TENX, MAAQ, ANVS, RANI, SCYX, IMA, XCUR, KZR, AKTX, and RNTX

Should you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include Tenax Therapeutics (TENX), Mana Capital Acquisition (MAAQ), Annovis Bio (ANVS), Rani Therapeutics (RANI), SCYNEXIS (SCYX), ImageneBio (IMA), Exicure (XCUR), Kezar Life Sciences (KZR), Akari Therapeutics (AKTX), and Rein Therapeutics (RNTX). These companies are all part of the "pharmaceutical products" industry.

Mainz Biomed vs. Its Competitors

Mainz Biomed (NASDAQ:MYNZ) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

Mainz Biomed has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500.

Mainz Biomed currently has a consensus price target of $14.00, suggesting a potential upside of 845.95%. Tenax Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 157.88%. Given Mainz Biomed's higher possible upside, equities analysts clearly believe Mainz Biomed is more favorable than Tenax Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mainz Biomed
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Tenax Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83

1.7% of Tenax Therapeutics shares are owned by institutional investors. 3.7% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Tenax Therapeutics has lower revenue, but higher earnings than Mainz Biomed. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mainz Biomed$659.94K12.14-$21.65M-$65.60-0.02
Tenax TherapeuticsN/AN/A-$17.60M-$0.92-7.59

Mainz Biomed's return on equity of 0.00% beat Tenax Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Mainz BiomedN/A N/A N/A
Tenax Therapeutics N/A -31.34%-30.39%

In the previous week, Mainz Biomed had 2 more articles in the media than Tenax Therapeutics. MarketBeat recorded 5 mentions for Mainz Biomed and 3 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 0.63 beat Mainz Biomed's score of -0.01 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mainz Biomed
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tenax Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Tenax Therapeutics beats Mainz Biomed on 9 of the 15 factors compared between the two stocks.

Get Mainz Biomed News Delivered to You Automatically

Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYNZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MYNZ vs. The Competition

MetricMainz BiomedMED IndustryMedical SectorNASDAQ Exchange
Market Cap$8.01M$3.39B$6.04B$10.49B
Dividend YieldN/A2.30%5.73%4.80%
P/E Ratio-0.0222.9085.1927.32
Price / Sales12.14269.18516.16194.55
Price / CashN/A46.9537.5761.53
Price / Book0.5710.5312.426.81
Net Income-$21.65M-$52.58M$3.32B$276.59M
7 Day Performance-7.50%1.06%0.80%0.15%
1 Month Performance-6.03%16.05%10.52%8.17%
1 Year Performance-87.11%18.41%76.14%35.50%

Mainz Biomed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MYNZ
Mainz Biomed
3.0209 of 5 stars
$1.48
-3.9%
$14.00
+845.9%
-88.0%$8.01M$659.94K-0.0230Analyst Forecast
TENX
Tenax Therapeutics
2.6346 of 5 stars
$7.41
-0.7%
$18.00
+142.9%
+98.2%$34.04MN/A-8.059Analyst Forecast
MAAQ
Mana Capital Acquisition
N/A$4.15
-8.8%
N/A-26.0%$33.72MN/A0.001Gap Down
ANVS
Annovis Bio
2.8676 of 5 stars
$1.64
-3.8%
$17.33
+960.1%
-77.6%$33.13MN/A-0.803Gap Down
RANI
Rani Therapeutics
3.3452 of 5 stars
$0.47
+2.2%
$7.33
+1,465.3%
-84.8%$32.93M$1.03M-0.51110
SCYX
SCYNEXIS
0.8351 of 5 stars
$0.81
+5.5%
N/A-46.9%$32.28M$3.75M-2.0360News Coverage
Analyst Forecast
Gap Up
Trading Halted
High Trading Volume
IMA
ImageneBio
3.3634 of 5 stars
$7.69
-3.4%
$35.50
+361.6%
-63.0%$31.88M$9.16M-1.0070Positive News
XCUR
Exicure
1.9158 of 5 stars
$5.14
+3.8%
N/A+97.7%$31.27M$500K-1.3250High Trading Volume
KZR
Kezar Life Sciences
3.6976 of 5 stars
$4.29
+1.7%
$9.00
+109.8%
-50.2%$30.90M$7M-0.4460
AKTX
Akari Therapeutics
3.1516 of 5 stars
$0.94
+1.3%
$3.30
+250.4%
-63.0%$30.33MN/A0.009News Coverage
Gap Down
RNTX
Rein Therapeutics
3.1322 of 5 stars
$1.32
+1.5%
$10.00
+657.6%
N/A$30.30MN/A-0.499

Related Companies and Tools


This page (NASDAQ:MYNZ) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners